Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

141 Results

Guidelines and Advice

Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery

Status: Current
ID: GL 17-12
Version: N/A

Sep 2019

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Status: Current
ID: 7-A-2018-2
Version: N/A

Jan 2020

Guidelines and Advice

Locoregional Management of In-Transit Metastasis in Melanoma

Status: Current
ID: GL 8-10
Version: N/A

Dec 1969

Guidelines and Advice

Regional Therapies for Colorectal Cancer Liver Metastases

Status: Current
ID: GL 2-30a
Version: N/A

Mar 2020

Guidelines and Advice

Pandemic Planning Clinical Guideline for Patients with Cancer

Status: Current
Version: 2

Dec 1969

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Dec 1969

Guidelines and Advice

Person-Centred Virtual Cancer Care Clinical Guidance

Status: Current
Version: 2

Jan 2022

Guidelines and Advice

Enhancing the Delivery of Oncology Systemic Treatment in the Home and Community in Ontario Recommendations Report

Status: Current
Version: 1

Dec 1969

Guidelines and Advice

Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment

Status: Current

Sep 2022

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 1

Dec 1969

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Dec 1969

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Locoregional Management of In-Transit Metastasis in Melanoma

Regional Therapies for Colorectal Cancer Liver Metastases

Pandemic Planning Clinical Guideline for Patients with Cancer

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Person-Centred Virtual Cancer Care Clinical Guidance

Enhancing the Delivery of Oncology Systemic Treatment in the Home and Community in Ontario Recommendations Report

Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Pages